Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 7/20 | 0.43 |
| ▸ | MMP9 | P14780 | 7/20 | 0.43 |
| ▸ | MMP8 | P22894 | 7/20 | 0.43 |
| ▸ | MMP13 | P45452 | 7/20 | 0.43 |
| ▸ | DGAT1 | O75907 | 7/20 | 0.41 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | F2RL1 | P55085 | 1/20 | 0.38 |
| ▸ | GBA1 | P04062 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13139263 | 0.86 | MMP2 (0.46) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL13139271 | 0.86 | MMP2 (0.46) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL22473656 | 0.84 | ZDHHC20 (0.49) | DGAT1ZDHHC20GBA1 | |
| SCHEMBL13695965 | 0.82 | DGAT1 (0.45) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL13139260 | 0.81 | MMP2 (0.43) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL13139268 | 0.81 | MMP2 (0.43) | MMP2MMP9MMP8MMP13DGAT1 | |
| SCHEMBL22083577 | 0.81 | DRD2 (0.44) | GBA1FOLH1 | |
| SCHEMBL21118389 | 0.81 | DGAT1 (0.47) | DGAT1ZDHHC20GBA1 | |
| SCHEMBL25978189 | 0.79 | GBA1 (0.48) | GBA1 | |
| SCHEMBL26032229 | 0.79 | GLP1R (0.39) | ZDHHC20CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120121509-A1 | VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE | THE GENERAL HOSPITAL CORPORATION (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120121509-A1 | VITAL FLUOROCHROME CONJUGATES AND METHODS OF USE | CASP3, CASP7, CD47 | MMP2 3890/4885MMP9 4572/4885MMP8 1940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.